PRKDC and lung carcinoma: To evaluate the impact of CC-115 inhibition of mTOR kinase and DNA-PK, CC-115 was tested in vitro across a panel of 123 cancer cell lines composed of 40 lymphoma and leukemia, 22 breast cancer, 11 hepatocellular carcinoma, 11 head and neck cancer, and 39 lung cancer cell lines.